Issue: June 25, 2015
May 31, 2015
2 min read
Save

Findings support wider excision margins in melanoma

Issue: June 25, 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — A surgical excision margin of 3 cm yielded significantly improved disease-specific survival but not OS in a cohort of patients with high-risk melanoma, according to findings presented at the ASCO Annual Meeting.

Perspective from Sanjay Awasthi, MD

Andrew J. Hayes, MD, of The Royal Marsden National Health Service Trust London, compared 1 cm and 3 cm clinical excision margins in a cohort of 900 high-risk patients with primary cutaneous melanoma who had a Breslow thickness of at least 2 mm.

Researchers randomly assigned 453 patients to undergo surgery with a 1 cm clinical excision margin and 447 patients to a 3 cm clinical excision margin. The two arms were balanced in terms of median tumor thickness and percentage of ulceration.

The median follow-up duration was 8.8 years (interquartile range, 6.3-11.3). There have been 494 deaths, of which 359 were associated with melanoma.

Univariate analysis results demonstrated a 24% increase in melanoma-related mortality in the 1-cm group compared with the 3-cm group (HR = 1.24; 95% CI, 1-1.52). This trend persisted in multivariate analysis (HR = 1.27; 95% CI, 1.02-1.59).

The number of overall deaths was higher in the 1 cm group (253 vs. 241), but univariable results indicated that the difference was not statistically significant (HR = 1.14; 95% CI, 0.96 to 1.36).

Results of the multivariable analysis also indicated 1 cm excision margins increased the risk for death compared with 3 cm excision margins, but the association did not reach statistical significance (HR = 1.19; 95% CI, 0.99-1.45).

“In multivariate analysis, we saw the usual suspects in terms of prognosis, including sex, thickness, ulceration and site,” Hayes said.

Other findings demonstrated an OS rate of 54.3% among women and 45.7% among men (HR = 1.38; 95% CI, 1.11-1.71). The HR for melanoma-specific survival was 1.38 (95% CI, 1.07-1.17) for men compared with women.

Ulceration was absent in 61.6% of the cohort. When ulceration was present, the HR was 1.68 (95% CI, 1.38-2.04) for OS and 1.75 (95% CI, 1.39-2.2) for melanoma-specific survival.

Approximately one-third of disease sites were in the distal limb (31.6%), whereas 22.4% were in the proximal limb and 45.9% were in the trunk. Multivariate analyses indicated disease in the proximal limb impacted OS (HR = 1.23; 95% CI, 0.93-1.63) and melanoma-specific survival (HR = 1.44; 95% CI, 1.03-2.03). Researchers also reported OS (HR = 1.41; 95% CI, 1.09-1.81) and melanoma-specific survival (HR = 1.69; 95% CI, 1.24-2.29) for trunk disease sites.

“We have demonstrated a significant increase in melanoma-specific mortality associated with a 1 cm margin compared to a 3 cm excision margin,” Hayes said.